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Over the last 10 years since the introduction of non-vitamin K antagonist oral antico-
agulants (NOACs) into routine clinical practice our experience with these drugs has
increased tremendously, also in the context of patients undergoing electrophysiology
procedures. While some open questions remain, the available evidence indicates
that for the majority of cases, these interventions can safely be performed on
NOACs if study-based standard operating procedures are in place and followed. This
review summarizes the most current trial evidence and guidelines on the use of
NOACs for patients undergoing cardioversion, atrial fibrillation ablation, and device
implantations, based on previous work of the author and others.
Introduction
Based on the outcomes of four landmark randomized clini-
cal trials, non-vitamin K antagonist oral anticoagulants
(NOACs) have become the standard of care for stroke pre-
vention in atrial fibrillation (AF).1–6 As a result, many
patients undergoing electrophysiological procedures, in-
cluding cardioversion, ablation, and device implantations,
are treated with NOACs. The management of these
patients may differ from peri-interventional management
around other procedures such as general or orthopaedic
surgery in that they involve direct (ablation) or indirect
(cardioversion, device implantation) manipulation of the
heart and, importantly, the left atrium. As such, anticoagu-
lation management requires an even more refined balance
between stroke prevention and the risk of peri-
interventional bleeding. Over the last years, experience on
the efficacy and safety of NOACs in the context of patients
undergoing electrophysiology (EP) procedures has in-
creased tremendously. This review summarizes the most
current trial evidence, guidelines, and open questions re-
garding the use of NOACs for patients undergoing
cardioversion, AF ablation, and device implantations,
based on previous work of the author and others.7
Cardioversion
Patients with AF of 48h (or unknown) duration who are
undergoing electrical or pharmacological cardioversion
need to have effective oral anticoagulation established for
at least 3weeks prior to cardioversion based on current ESC
guidelines.5 Alternatively, LA/LAA thrombus may be ruled
out, e.g. by transoesophageal echocardiography (TOE).
Oral anticoagulation has to be continued for at least an-
other 4weeks following cardioversion. These recommenda-
tions are independent of the mode of cardioversion
(electrical vs. medical) as well as the CHA2DS2-VASc score
and have hence to be followed also in patients with a score
of 0 who otherwise do not qualify for long-term anticoagu-
lation.5,6 The rationale behind this seeming inconsistency
has traditionally been the belief that the risk of thrombo-
embolism is increased after cardioversion due to dislodge-
ment of a pre-existing thrombus or temporary reduction in
atrial function resulting in new thrombus formation.8
Recent evidence has challenged the causal relationship of
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cardioversion indicating that the latter may at least in part
be due to overall clinical deterioration of these patients
(resulting in the need for cardioversion).9 As such, the
mere necessity for cardioversion may (also) be a marker of
a larger overall disease burden rather of than (purely) a
causal factor for ischaemic events.
In patients requiring cardioversion, two different scenar-
ios have to be distinguished:
(1) Cardioversion in patients newly diagnosed with AF
and naı̈ve to anticoagulation.
(2) Cardioversion in patients on chronic treatment with
a NOAC
Cardioversion in patients not on non-vitamin K
antagonist oral anticoagulants therapy
Dedicated studies have been performed for the scenario of
cardioversion in AF patients not on a NOAC. The
EMANATE,10 ENSURE-AF,11 and X-VeRT12 trials with apixa-
ban, edoxaban, and rivaroxaban, respectively, included
100%, 27%, and 57% of oral anticoagulation (OAC)-naı̈ve
patients, respectively.7 The majority of patients included
in these trials had AF of 48h (or unknown) duration. Two
different strategies were investigated: Patients were ei-
ther cardioverted early (after exclusion of LA/LAA throm-
bus via TOE) or delayed after 3–8weeks of anticoagulation
before cardioversion. Except for a lower rate of ischaemic
events with apixaban in the EMANATE trial, there were no
differences in ischaemic or bleeding events between the
NOAC- and the group using VKA. Similarly, no difference be-
tween the early and delayed group was observed. Overall,
event rates were (expectedly) low and as such, the trials
were formally not powered for non-inferiority. In the
EMANATE trial, an initial loading dose of 10mg of apixaban
(5mg if does-adjustment criteria were met) was adminis-
tered in 45% of patients.
Taken together, these data indicate that performing a
cardioversion in a patient with AF of 48 h duration either
after 3weeks of NOAC therapy or using at least a single
NOAC dose 4h before cardioversion (2h after apixaban
loading dose) after exclusion of a LA/LAA thrombus appears
safe and effective.7 Importantly, adherence needs to be as-
sured in patients cardioverted after 3weeks of NOAC ther-
apy and, if in doubt, exclusion of LA/LAA thrombus is
nonetheless recommended.
Observational studies have indicated a lower incidence
of ischaemic events using anticoagulation even in patients
with AF duration of <48 h, especially in individuals with an
elevated CHA2DS2-VASc score 2 and AF duration
12h.7,13,14 These patients were not included to a great
enough extent in the above-mentioned pivotal cardiover-
sion trials in order to make any firm recommendations. In
the pre-NOAC era, they were usually cardioverted follow-
ing administration of a single dose of LMWH, followed by
VKA treatment for at least 4weeks (if CHA2DS2-VASc score
0 in men or 1 in women) or life-long (in all other patients).
In view of the similar pharmacokinetic and pharmacody-
namic properties of NOACs vs. LMWH and the similar results
in patients on NOACs vs. LMWH/VKA in patients cardio-
verted after 48h duration AF, the use of NOACs appears
justifiable also in these situations.7 Independent of the
mode of therapy, LA/LAA thrombus should be ruled out or
anticoagulation installed for 3weeks prior to cardiover-
sion in very high risk patients (i.e. CHA2DS2-VASc  4) and
in those in whom there is any doubt about the onset of AF.7
Cardioversion in atrial fibrillation patients on
non-vitamin K antagonist oral anticoagulant
therapy for 3weeks
Several thousand cardioversions were performed in the
landmark phase III NOAC trials in patients on apixaban,3
dabigatran,1 edoxaban,15 or rivaroxaban.2 Overall, the risk
of ischaemic as well as bleeding events following cardiover-
sion were very low and similar compared to patients under-
going cardioversion under warfarin. These results were
later confirmed in the above-discussed dedicated cardio-
version trials as well as in various meta-analyses and ‘real
world’ studies.16–18 Although none of these studies include
sufficient patient numbers to formally demonstrate statis-
tically non-inferiority, the available evidence strongly sug-
gests that cardioversion under regular and continued NOAC
intake is reasonably safe.5,7 One important prerequisite,
however, is adequate adherence and correct (on-label)
dosing of NOAC therapy prior to cardioversion. If this can-
not be guaranteed LA/LAA thrombus should be ruled out
with imaging prior to cardioversion. Finally, thrombi may
also develop under adequate anticoagulation therapy,19–21
which is why one may opt to anyways perform imaging
even in case of long-standing anticoagulation prior to car-
dioversion. Conversely, not all strokes in patients with AF
may be due to thrombi in the LA/LAA; as such, any (rare)
ischaemic event in the time period after cardioversion—
even on adequate anticoagulation—may not be the result
of an undetected LA/LAA thrombus.
Duration of anticoagulation post-cardioversion
Patients with a CHA2DS2-VASc score of 2 (women) or 1
(men) have a Class IIa indication for life-long anticoagula-
tion independent of cardioversion, while a Class I indica-
tion is given in case of a score3 (women) and 2 (men).5
However, in patients with a CHA2DS2-VASc score of 1
(women) or 0 (men), the situation is less clear. While cur-
rent guidelines recommend 4weeks of anticoagulation if
AF duration was 48h prior to cardioversion data are
scarce for patients with shorter durations, especially
<12h.7 Importantly, these patients may in addition have
self-limiting (i.e. ‘self-cardioverting’) bouts of AF of sev-
eral hours’ duration (which may be asymptomatic) for
which it is unclear whether OAC should be recommended.
Given the overall very low risk of thromboembolism in
these patients and the usually comparatively good general
health, longer and particularly life-long anticoagulation
does generally not seem to be mandated, but further stud-
ies are necessary.
Management of left atrial/left atrial appendage
thrombus
In the absence of an emergency indication cardioversion
should be deferred in patients in whom an LA/LAA throm-
bus is detected. There are no (and likely never will be any)
adequately powered endpoint trials comparing a LMWH/
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VKA based regimen to NOACs for the treatment of LA/LAA
thrombi. Increasing observational evidence is indicating a
similar degree of thrombus resolution using a NOAC vs. a
LMWH/VKA based regimen.22–24 In the prospective X-TRA
study, thrombus resolution was observed in 22 out of 53
patients (41.5%) with standard dose rivaroxaban,25which is
comparable to the resolution rate under heparin/VKA in
the retrospective CLOT-AF registry (60/96 patients,
62.5%).25 Similarly the rate of thrombus resolution was sim-
ilar in patients treated with apixaban (52%, 12/23) as com-
pared to LMWH/VKA (56%, 10/18) in the EMANATE trial.26
The prospective RE-LATED AF study with dabigatran has re-
cently been terminated due to recruitment problems
(NCT02256683, accessed 10 January 2020). Importantly,
mal-adherence as well as off-label use of reduced NOAC
dose were shown to be among the main predictors for the
development of LA/LAA thrombus ‘under’ NOAC therapy.24
Conversely, increased dosage or changing the anticoagu-
lant strategy appeared to be successful in thrombus
resolution.24
Taken together, increasing evidence indicates that
NOACs may be a valid option for LA/LAA thrombus resolu-
tion. This appears particularly appealing in patients in
whom VKA are not well tolerated or in whom an adequate
time in therapeutic range cannot be achieved.7
Atrial fibrillation ablation
Although the absolute incidence in experienced hands is
decreasing, left atrial catheter ablation still carries a risk
of both severe ischaemic and bleeding complications,
mainly related to transseptal puncture and ablation in the
left atrium.27,28 In patients on VKA, ablation is recom-
mended to be performed on uninterrupted therapy with a
target international normalized ratio 2–2.5,5,27 as this has
been shown to lead to less thromboembolic as well as
bleeding complications compared to a LMWH/UFH heparin-
based bridging strategy.29 Over the last years, dedicated
randomized clinical trials for apixaban (AXAFA),30 dabiga-
tran (RE-CIRCUIT),31 edoxaban (ELIMINATE),32 and rivarox-
aban33 have been performed each comparing
uninterrupted NOAC to uninterrupted VKA treatment
around catheter ablation for AF. Importantly, bid-based
NOACs (apixaban, dabigatran) were administered in the
morning of the procedure, whereas the last dose of once-
daily based NOACs were recommended (rivaroxaban) or
mandated (edoxaban) to be administered in the evening
before the procedure (Figure 1). Although the studies were
underpowered to detect statistically significant differen-
ces in hard endpoints, the overall event rate in the NOAC
arms of the trials were low, while large variations in the
event rate in the VKA arm of the trials were observed. A
lower rate of bleeding events was confirmed in a recent
meta-analysis of 29 studies comprising over 12 000
patients.34 As such, it may be concluded that the use of
uninterrupted NOAC therapy can be considered safe and
effective and should likely be preferred to uninterrupted
VKA treatment in patients undergoing AF ablation.
Whether to give or withhold the morning dose before abla-
tion may depend on various factors. In spite of the positive
trial evidence operators may not be entirely comfortable
performing groyne puncture, transseptal puncture and
left-sided ablation at peak NOAC plasma levels. On the flip-
side, however, patients may be exposed to very low antico-
agulant levels following the procedure if the morning dose
is withheld, particularly if protamine is delivered prior to
sheath removal. It may therefore be advisable to adminis-
ter the morning dose prior to ablation if intraprocedural
heparin administration is routinely reversed prior to sheath
removal, or if the first dose of heparin is administered only
after successful transseptal puncture. If, conversely, the
peri-interventional protocol includes administration of a
first bolus of unfractionated heparin just prior to the first
transseptal puncture, closure of the groyne puncture
(e.g. with a figure-of-eight stitch or a dedicated closure
device) without administration of protamine, and re-
sumption of full dose NOAC therapy 4–6 h post sheath re-
moval, withholding the morning dose of the NOAC
appears justifiable as the patient is unlikely to be ex-
posed to low anticoagulant levels at any point in time.
Randomized clinical trial evidence comparing these two
approached, however, are not available. In once-daily
based NOACs, switching NOAC intake to the evening well
in advance (e.g. 1week) of the intervention appears rea-
sonable in order to follow a similar protocol as in the re-
spective clinical trials.32,33
Current expert consensus statements generally recom-
mend to routinely consider exclusion of an LA/LAA throm-
bus prior to AF ablation.7,27 While TOE (or intracardiac
imaging) is currently considered the standard of care to
rule out LA/LAA thrombus, computed tomography (CT)
may represent an attractive alternative35 especially since
a large number of patients will anyways undergo CT imag-
ing prior to ablation for LA anatomy assessment and 3D re-
construction. Performance of the CT shortly prior to the
ablation (as for TOE), implementation of a dedicated CT

















Figure 1: Management of non-vitamin K antagonist oral anticoagulants around atrial fibrillation ablation (based on reference 7). See text for details.
Consider administration of twice-daily dosed non-vitamin K antagonist oral anticoagulants in the morning of the procedure especially if no administration
of heparin prior to transseptal puncture is administered and when periprocedural heparin anticoagulation is reversed prior to sheath removal. *Patients
on once-daily dosed non-vitamin K antagonist oral anticoagulants (edoxaban, rivaroxaban) are recommended to be switched to evening intake well be-
fore the planned atrial fibrillation ablation.
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interpretation of CTs in this indication are crucial prerequi-
sites. In case of doubts or inconclusive CT imaging results,
performance of a TOE is mandatory.
During AF ablation, intravenous heparin with a target ac-
tivated clotting time (ACT) of 300–350 s should be adminis-
tered.7,27,36 The total dose of heparin and time to reach
the target ACT is generally higher in patients undergoing
AF ablation on NOACs vs. VKA,37–39 reflecting a difference
in whole blood coagulability.
Device implantation procedures
In experienced hands, implantation of cardiac device (i.e.
pacemaker, implantable cardioverter defibrillator (ICD),
and cardiac resynchronization therapy (CRT) devices) and
generator exchanges are generally procedures with a low
bleeding risk. Uninterrupted VKA treatment has been
shown to lead to fewer bleeding events as compared to
heparin-based bridging in patients undergoing device im-
plantation on VKA in the prospective randomized BRUISE-
CONTROL trial.40 The BRUISE-CONTROL 2 trial demon-
strated that patients on uninterrupted NOAC therapy (in-
cluding intake in the morning of the procedure) have a
similarly low rate of relevant bleeding complications as
those with a last intake 48h before the procedure.41 Other
complications were rare, including one stroke and one
symptomatic pericardial effusion. Further evidence for a
low overall complication rate, including both bleeding and
ischaemic events, comes from several registries42 as well
as from the PAUSE43 and the EMITstudies in which a various
amount of patients undergoing cardiac device procedures
on either continued or minimally uninterrupted NOAC ther-
apy have been included, and in which low incidence of
bleeding and ischaemic event rates were confirmed. As
such, the standard strategy suggested for ‘low bleeding
risk’ procedures in the current EHRA44 Practical Guide on
the use of NOACs with intake of the last NOAC dose in the
morning or evening of the day before the procedure seems
reasonable in most cases, followed by restarting one day
afterwards (adequate haemostasis provided, Figure 2).7
The role of NOAC plasma levelmeasurements prior to de-
vice surgery (or, for that matter, any type of surgery) is cur-
rently unclear due to the lack of adequately powered
prospective clinical trial data. Importantly, it is unclear
whether the benefit of withholding NOACs for a longer
time period based on an elevated NOAC plasma level
outweighs the risk of prolonged interruption of
anticoagulation.7 Based on the available evidence dis-
cussed above, routine NOAC plasma level assessments are
not recommended. Whether such a strategy may be of use
in very high risk situations such as severe renal insuffi-
ciency, multiple possible drug–drug interactions, very high
risk interventions (including difficult lead extractions) etc.
will require further studies.
Summary and conclusions
Over the last 10years since the introduction of NOACs into
routine clinical practice, our experience with these drugs
has increased tremendously, also in the context of patients
undergoing EP procedures. Some open questions remain:
how long should low-risk patients (CHA2DS2-VASc 0 in men,
1 in women) be anticoagulated following cardioversion?
Can NOACs safely and effectively be used to ‘dissolve’ a
thrombus in the LA/LAA? Is ‘truly’ uninterrupted NOAC
therapy safer and more effective as leaving out the morn-
ing dose of the NOAC before AF ablation? What is the opti-
mal NOAC treatment strategy around higher risk cardiac
device interventions such as transvenous lead extraction?
These questions will require further data, ideally in the
form of dedicated randomized trials to be solved; addition-
ally, data from partly already ongoing large registries will
be of value (with the main limitation of unmeasured con-
founding). This notwithstanding the available evidence to-
day indicates that for the majority of cases, EP procedures
like cardioversion, ablation, and device implantations can
safely be performed on NOACs if study-based standard op-
erating procedures are in place and followed.
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